Key Drivers
- Cash Cushion
- Deep Losses
- Rich Valuation
AIAI Summary
TNGX should now be viewed less as a cash-risk biotech and more as a well-funded, data-dependent clinical name with runway into 2028, where the investment case hinges on near-term readouts from vopimetostat, TNG456, and PRMT5/RAS(ON) combinations validating the pipeline before the market re-rates it lower on disappointment.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •Deep Losses
- •Rich Valuation
TNGX has a strong cash-rich balance sheet with low debt, but persistent heavy losses, negative cash flow, and a rich sales/book valuation make the stock fundamentally risky.
Price Behavior
Key Price Behavior Insights:
- •Failed breakout
- •Sharp reversal
- •Support test
Over the last month, TNGX shifted from a strong rally to a short-term downtrend, with a failed rebound near $26.9-$27.0, support around $20.5-$21.0, and downside risk now outweighing upside.
Sharp drop from $24.87 on 2026-05-14 to $20.55 on 2026-05-15 after a brief rebound
Sentiment & News
Key News Insights:
- •Cash runway
- •Trial catalyst
- •Mixed ownership
Tango Therapeutics showed constructive clinical and financial momentum, with a strong cash runway, upcoming PRMT5/RAS(ON) data, and mixed ownership signals from institutional buying and insider selling.
The news is modestly positive for Tango Therapeutics, as strong liquidity and upcoming clinical data support the investment case despite mixed trading signals
Similar Companies in Healthcare
Other companies in the same sector with AI ratings